A Randomized, Open-labeled, Multi-center, Active-controlled, Parallel-group Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 versus NTCB-C in patients who require parenteral nutrition
Those who are 19 years old or older at the screening visit
Patients are expected to require PN for more than 3 days
Patients who voluntarily signed the consent form
Patients are expected difficult to survive more than 3 days
Patients BMI is over 30 kg/m2
Patients having hypersensitivity to any peanut-, fish-, soy-, egg protein, or investigational drug
Patients with difficult central venous line